tiprankstipranks
Advertisement
Advertisement
Helus Pharma initiated with an Overweight at Wells Fargo
PremiumThe FlyHelus Pharma initiated with an Overweight at Wells Fargo
16d ago
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
Premium
The Fly
Psychedelic: PharmAla enters license agreement with Jupiter Neurosciences
20d ago
Helus Pharma: Late-Stage Psychedelic Depression Data Seen as Near-Term Catalyst; Buy Rating Reaffirmed with Unchanged $70 Target
Premium
Ratings
Helus Pharma: Late-Stage Psychedelic Depression Data Seen as Near-Term Catalyst; Buy Rating Reaffirmed with Unchanged $70 Target
21d ago
AtaiBeckley downgraded to Hold from Buy at JonesResearch
PremiumThe FlyAtaiBeckley downgraded to Hold from Buy at JonesResearch
27d ago
FDA announces availability of final guidance for psychedelic drug research
Premium
The Fly
FDA announces availability of final guidance for psychedelic drug research
28d ago
Helus Pharma price target lowered to $15 from $30 at Alliance Global
Premium
The Fly
Helus Pharma price target lowered to $15 from $30 at Alliance Global
29d ago
Psychedelic: Helus Pharma reports FY26 financial results
PremiumThe FlyPsychedelic: Helus Pharma reports FY26 financial results
1M ago
Helus Pharma price target lowered to $42 from $45 at Canaccord
Premium
The Fly
Helus Pharma price target lowered to $42 from $45 at Canaccord
1M ago
Helus Pharma Bolsters Balance Sheet as Late-Stage Mental Health Pipeline Advances and Losses Widen
Premium
Company Announcements
Helus Pharma Bolsters Balance Sheet as Late-Stage Mental Health Pipeline Advances and Losses Widen
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100